Selected research
Industry Research
Mammalian Biopharmaceutical Service Industry Research Report 2026
Market perspective
The global Mammalian Biopharmaceutical Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Mammalian Biopharmaceutical Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Mammalian Biopharmaceutical Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Mammalian Biopharmaceutical Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Mammalian Biopharmaceutical Service include Novartis, KBI Biopharma, 3P Biopharmaceuticals, Sartorius Stedim Biotech, Merck Millipore, Rentschler Biopharma SE, Northway Biotech, Cambrex and Samsung Biologics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Mammalian Biopharmaceutical Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Mammalian Biopharmaceutical Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mammalian Biopharmaceutical Service Market by Company
Novartis
KBI Biopharma
3P Biopharmaceuticals
Sartorius Stedim Biotech
Merck Millipore
Rentschler Biopharma SE
Northway Biotech
Cambrex
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
GBI
Thermo Fisher Scientific
Catalent
WuXi Biologics
Boehringer Ingelheim BioXcellence
Lonza
Abzena
AGC Biologics
Mammalian Biopharmaceutical Service Segment by Type
Cell Line Development
Analytical Testing
Technology Transfer
Formulation Development
Others
Mammalian Biopharmaceutical Service Segment by Application
Pharmaceutical
Contract Research Organizations (CROs)
Academic and Research Institutes
Biotechnology Companies
Government Agencies
Mammalian Biopharmaceutical Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mammalian Biopharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mammalian Biopharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mammalian Biopharmaceutical Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Mammalian Biopharmaceutical Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Line Development
- Analytical Testing
- Technology Transfer
- Formulation Development
- Others
Applications
- Pharmaceutical
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Biotechnology Companies
- Government Agencies
Companies covered
- Novartis
- KBI Biopharma
- 3P Biopharmaceuticals
- Sartorius Stedim Biotech
- Merck Millipore
- Rentschler Biopharma SE
- Northway Biotech
- Cambrex
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- GBI
- Thermo Fisher Scientific
- Catalent
- WuXi Biologics
- Boehringer Ingelheim BioXcellence
- Lonza
- Abzena
- AGC Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Mammalian Biopharmaceutical Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cell Line Development
- 2.2.3 Analytical Testing
- 2.2.4 Technology Transfer
- 2.2.5 Formulation Development
- 2.2.6 Others
- 2.3 Mammalian Biopharmaceutical Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical
- 2.3.3 Contract Research Organizations (CROs)
- 2.3.4 Academic and Research Institutes
- 2.3.5 Biotechnology Companies
- 2.3.6 Government Agencies
- 2.4 Assumptions and Limitations
3 Mammalian Biopharmaceutical Service Breakdown Data by Type
- 3.1 Global Mammalian Biopharmaceutical Service Historic Market Size by Type (2021-2026)
- 3.2 Global Mammalian Biopharmaceutical Service Forecasted Market Size by Type (2027-2032)
4 Mammalian Biopharmaceutical Service Breakdown Data by Application
- 4.1 Global Mammalian Biopharmaceutical Service Historic Market Size by Application (2021-2026)
- 4.2 Global Mammalian Biopharmaceutical Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Mammalian Biopharmaceutical Service Market Perspective (2021-2032)
- 5.2 Global Mammalian Biopharmaceutical Service Growth Trends by Region
- 5.2.1 Global Mammalian Biopharmaceutical Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Mammalian Biopharmaceutical Service Historic Market Size by Region (2021-2026)
- 5.2.3 Mammalian Biopharmaceutical Service Forecasted Market Size by Region (2027-2032)
- 5.3 Mammalian Biopharmaceutical Service Market Dynamics
- 5.3.1 Mammalian Biopharmaceutical Service Industry Trends
- 5.3.2 Mammalian Biopharmaceutical Service Market Drivers
- 5.3.3 Mammalian Biopharmaceutical Service Market Challenges
- 5.3.4 Mammalian Biopharmaceutical Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Mammalian Biopharmaceutical Service Players by Revenue
- 6.1.1 Global Top Mammalian Biopharmaceutical Service Players by Revenue (2021-2026)
- 6.1.2 Global Mammalian Biopharmaceutical Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Mammalian Biopharmaceutical Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Mammalian Biopharmaceutical Service Head Office and Area Served
- 6.4 Global Mammalian Biopharmaceutical Service Players, Product Type & Application
- 6.5 Global Mammalian Biopharmaceutical Service Manufacturers Established Date
- 6.6 Global Mammalian Biopharmaceutical Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Mammalian Biopharmaceutical Service Market Size (2021-2032)
- 7.2 North America Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Mammalian Biopharmaceutical Service Market Size by Country (2021-2026)
- 7.4 North America Mammalian Biopharmaceutical Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Mammalian Biopharmaceutical Service Market Size (2021-2032)
- 8.2 Europe Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Mammalian Biopharmaceutical Service Market Size by Country (2021-2026)
- 8.4 Europe Mammalian Biopharmaceutical Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Mammalian Biopharmaceutical Service Market Size (2021-2032)
- 9.2 Asia-Pacific Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Mammalian Biopharmaceutical Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Mammalian Biopharmaceutical Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Mammalian Biopharmaceutical Service Market Size (2021-2032)
- 10.2 South America Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Mammalian Biopharmaceutical Service Market Size by Country (2021-2026)
- 10.4 South America Mammalian Biopharmaceutical Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Mammalian Biopharmaceutical Service Market Size (2021-2032)
- 11.2 Middle East & Africa Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Mammalian Biopharmaceutical Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Mammalian Biopharmaceutical Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.1.4 Novartis Mammalian Biopharmaceutical Service Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 KBI Biopharma
- 12.2.1 KBI Biopharma Company Information
- 12.2.2 KBI Biopharma Business Overview
- 12.2.3 KBI Biopharma Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.2.4 KBI Biopharma Mammalian Biopharmaceutical Service Product Portfolio
- 12.2.5 KBI Biopharma Recent Developments
- 12.3 3P Biopharmaceuticals
- 12.3.1 3P Biopharmaceuticals Company Information
- 12.3.2 3P Biopharmaceuticals Business Overview
- 12.3.3 3P Biopharmaceuticals Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.3.4 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Product Portfolio
- 12.3.5 3P Biopharmaceuticals Recent Developments
- 12.4 Sartorius Stedim Biotech
- 12.4.1 Sartorius Stedim Biotech Company Information
- 12.4.2 Sartorius Stedim Biotech Business Overview
- 12.4.3 Sartorius Stedim Biotech Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.4.4 Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Product Portfolio
- 12.4.5 Sartorius Stedim Biotech Recent Developments
- 12.5 Merck Millipore
- 12.5.1 Merck Millipore Company Information
- 12.5.2 Merck Millipore Business Overview
- 12.5.3 Merck Millipore Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.5.4 Merck Millipore Mammalian Biopharmaceutical Service Product Portfolio
- 12.5.5 Merck Millipore Recent Developments
- 12.6 Rentschler Biopharma SE
- 12.6.1 Rentschler Biopharma SE Company Information
- 12.6.2 Rentschler Biopharma SE Business Overview
- 12.6.3 Rentschler Biopharma SE Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.6.4 Rentschler Biopharma SE Mammalian Biopharmaceutical Service Product Portfolio
- 12.6.5 Rentschler Biopharma SE Recent Developments
- 12.7 Northway Biotech
- 12.7.1 Northway Biotech Company Information
- 12.7.2 Northway Biotech Business Overview
- 12.7.3 Northway Biotech Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.7.4 Northway Biotech Mammalian Biopharmaceutical Service Product Portfolio
- 12.7.5 Northway Biotech Recent Developments
- 12.8 Cambrex
- 12.8.1 Cambrex Company Information
- 12.8.2 Cambrex Business Overview
- 12.8.3 Cambrex Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.8.4 Cambrex Mammalian Biopharmaceutical Service Product Portfolio
- 12.8.5 Cambrex Recent Developments
- 12.9 Samsung Biologics
- 12.9.1 Samsung Biologics Company Information
- 12.9.2 Samsung Biologics Business Overview
- 12.9.3 Samsung Biologics Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.9.4 Samsung Biologics Mammalian Biopharmaceutical Service Product Portfolio
- 12.9.5 Samsung Biologics Recent Developments
- 12.10 FUJIFILM Diosynth Biotechnologies
- 12.10.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.10.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.10.3 FUJIFILM Diosynth Biotechnologies Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.10.4 FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Product Portfolio
- 12.10.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.11 GBI
- 12.11.1 GBI Company Information
- 12.11.2 GBI Business Overview
- 12.11.3 GBI Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.11.4 GBI Mammalian Biopharmaceutical Service Product Portfolio
- 12.11.5 GBI Recent Developments
- 12.12 Thermo Fisher Scientific
- 12.12.1 Thermo Fisher Scientific Company Information
- 12.12.2 Thermo Fisher Scientific Business Overview
- 12.12.3 Thermo Fisher Scientific Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.12.4 Thermo Fisher Scientific Mammalian Biopharmaceutical Service Product Portfolio
- 12.12.5 Thermo Fisher Scientific Recent Developments
- 12.13 Catalent
- 12.13.1 Catalent Company Information
- 12.13.2 Catalent Business Overview
- 12.13.3 Catalent Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.13.4 Catalent Mammalian Biopharmaceutical Service Product Portfolio
- 12.13.5 Catalent Recent Developments
- 12.14 WuXi Biologics
- 12.14.1 WuXi Biologics Company Information
- 12.14.2 WuXi Biologics Business Overview
- 12.14.3 WuXi Biologics Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.14.4 WuXi Biologics Mammalian Biopharmaceutical Service Product Portfolio
- 12.14.5 WuXi Biologics Recent Developments
- 12.15 Boehringer Ingelheim BioXcellence
- 12.15.1 Boehringer Ingelheim BioXcellence Company Information
- 12.15.2 Boehringer Ingelheim BioXcellence Business Overview
- 12.15.3 Boehringer Ingelheim BioXcellence Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.15.4 Boehringer Ingelheim BioXcellence Mammalian Biopharmaceutical Service Product Portfolio
- 12.15.5 Boehringer Ingelheim BioXcellence Recent Developments
- 12.16 Lonza
- 12.16.1 Lonza Company Information
- 12.16.2 Lonza Business Overview
- 12.16.3 Lonza Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.16.4 Lonza Mammalian Biopharmaceutical Service Product Portfolio
- 12.16.5 Lonza Recent Developments
- 12.17 Abzena
- 12.17.1 Abzena Company Information
- 12.17.2 Abzena Business Overview
- 12.17.3 Abzena Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.17.4 Abzena Mammalian Biopharmaceutical Service Product Portfolio
- 12.17.5 Abzena Recent Developments
- 12.18 AGC Biologics
- 12.18.1 AGC Biologics Company Information
- 12.18.2 AGC Biologics Business Overview
- 12.18.3 AGC Biologics Revenue in Mammalian Biopharmaceutical Service Business (2021-2026)
- 12.18.4 AGC Biologics Mammalian Biopharmaceutical Service Product Portfolio
- 12.18.5 AGC Biologics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst